SU6668

SU6668 is an ATP-competitive PDGFR, Flk-1/KDR and FGFR inhibitor. It presents little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2. It does not inhibit EGFR. SU6668 inhibits proliferation of HUVEC and NIH3T3 cells in-vitro and induces >75% growth inhibition against a broad range of tumor types. SU6668 shows antiangiogenic, anti-inflammatory, antimetastatic and proapototic activity and is orally active.